{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:42Z","timestamp":1793730942615,"version":"4.6.1"},"reference-count":24,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s230592","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T21:11:45Z","timestamp":1603833105000},"page":"1031-1037","source":"Crossref","is-referenced-by-count":49,"title":["<p>Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential<\/p>"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Constantine E","family":"Kosmas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Mu\u00f1oz Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Skavdis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edilberto","family":"Pe\u00f1a Genao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliscer","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"GBD 2017 Causes of Death Collaborators. Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736\u20131788.","DOI":"10.1016\/S0140-6736(18)32203-7"},{"key":"ref2","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.5114\/aoms.2012.30281","volume":"8","author":"Rizzo","year":"2012","journal-title":"Arch Med Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1517\/14656560903376186","volume":"10","author":"Bates","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2013.03.041","volume":"112","author":"Wong","year":"2013","journal-title":"Am J Cardiol"},{"key":"ref8","first-page":"843","volume":"6","author":"Lardizabal","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","volume":"357","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","volume":"155","author":"Ho","year":"2008","journal-title":"Am Heart J"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.2147\/PPA.S149423","volume":"12","author":"Kosmas","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"212511","DOI":"10.7573\/dic.212511","volume":"6","author":"Kosmas","year":"2017","journal-title":"Drugs Context"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/diseases6030063","volume":"6","author":"Kosmas","year":"2018","journal-title":"Diseases"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc18-1491","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol"},{"key":"ref19","unstructured":"Kastelein JJ, et al. Late Breakers. Long-term inclisiran in subjects with high CV risk and elevated LDL-C. Presented at: National Lipid Association Scientific Sessions; May 16\u201319, 2019; Miami."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"ref22","unstructured":"A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ORION-5). ClinicalTrials.gov Identifier: NCT03851705. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03851705. Accessed August 22, 2020."},{"key":"ref23","first-page":"30866","volume":"S0002\u20139149","author":"Khan","year":"2020","journal-title":"Am J Cardiol"},{"key":"ref24","unstructured":"A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4). ClinicalTrials.gov Identifier: NCT03705234. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03705234. Accessed August 22, 2020."}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=63015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=63015","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T21:12:14Z","timestamp":1603833134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/inclisiran-for-the-treatment-of-cardiovascular-disease-a-short-review--peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s230592","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}